In the phase 1b portion of the MELT-MM trial, elranatamab plus mezigdomide produced a 100% overall response rate in relapsed/refractory multiple myeloma.
News|Articles|September 18, 2024
Conference Compendium: The Top 10 Takeaways From ESMO 2024
Author(s)Russ Conroy
Fact checked by: Ariana Pelosci
ESMO 2024 saw a wide range of potentially practice-changing data across multiple oncology disciplines such as the breast cancer and lung cancer fields.
Advertisement
Advertisement
At the
Related to this article
A pooled analysis of the AMY2009 and AMY3001 trials showed daratumumab plus VCd yielded hematologic complete responses in cardiac-involved AL amyloidosis.
David R. Gandara, MD, discusses how EMPOWER-Lung 1’s findings in KRAS G12C-mutated disease should inform the design of combination trials.
Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.
Meletios A. Dimopoulos, MD, discussed where bispecific antibodies such as teclistamab may fit for patients with relapsed Waldenström macroglobulinemia.
In the LINKER-SMM1 trial, single-agent linvoseltamab produced a 100% overall response rate among evaluable patients with high-risk smoldering multiple myeloma.
David R. Gandara, MD, explains what makes KRAS G12C biologically distinct from other KRAS subtypes in NSCLC immunotherapy response.
Peter Forsyth, MD, discusses a first-in-human trial of intrathecal dendritic cell therapy for leptomeningeal disease from breast cancer.
Advertisement
Advertisement